Arcus Biosciences, Inc. has grown revenue 30% a year over three years and 4.7% a year over five. Revenue growth, 3-year annual rate: +30% (Biotechnology median +17%). Revenue growth, 5-year rate: +4.7%, growth has picked up over the last three years. Years of annual history on file: 10, FY2016 to FY2025, as filed.

RCUSArcus Biosciences, Inc.

Healthcare

$24.39+97% 1Y

$24.39

$12.3752 weeks$31.57

Is it growing?

Watch

Growth is fading: revenue shrinking (−55% year on year) and operating margin narrowing (−214.6 points).

2 to watch, 1 without data

Revenue trend−55% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +5% a year.

Margin direction−214.6 points operating

Trailing-twelve-month operating margin, -478.5% now against -263.9% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is RCUS growing?

Arcus Biosciences, Inc. has grown revenue 30% a year over three years and 4.7% a year over five.

+30%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +4.7%
Revenue growth, 5-year rate · +30% over three · growth has picked up over the last three years
Years of annual history on file: 10
Years of annual history on file · FY2016 to FY2025, as filed

Details›